Form 4: Trevi Therapeutics CEO Jennifer L. Good Granted Stock Options

Trevi Therapeutics CEO Jennifer L. Good was granted stock options to purchase 811,000 shares of common stock on February 18, 2025.

Summary

• On February 18, 2025, Jennifer L. Good, the President & CEO and a director of Trevi Therapeutics, Inc. (TRVI), was granted stock options.
• The options allow her to purchase 811,000 shares of Trevi Therapeutics common stock at an exercise price of $4.22 per share.
• The options vest as to 25% of the shares on February 18, 2026, and the remaining 75% vest in equal monthly installments through February 18, 2029.
• The options expire on February 17, 2035.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and generally viewed as a positive sign of aligning management's interests with shareholders. However, it's not a major event that would significantly impact the company's outlook.

Positives

• The granting of stock options to the CEO aligns her interests with those of the shareholders, incentivizing her to increase the company's value.
• The vesting schedule encourages long-term commitment from the CEO.

Future Outlook

The document does not contain any specific forward-looking statements or guidance beyond the vesting schedule of the stock options.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, used to attract and retain talent and align management's interests with those of shareholders. The size and vesting schedule of the grant are typical for a company of Trevi Therapeutics' size and stage of development.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Cara Therapeutics or Galena Biopharma, which are similar in market cap and focus, also utilize stock options to incentivize their executives.
• The vesting schedule of these options is fairly standard, with a multi-year vesting period to encourage long-term commitment.

Stakeholder Impact

• Shareholders: The stock option grant aligns the CEO's interests with increasing shareholder value.
• Employees: The grant could boost employee morale by demonstrating confidence in the company's future.

Key Dates

Keywords

stock options, Trevi Therapeutics, TRVI, Jennifer L. Good, executive compensation, Form 4, insider transaction